Back

HIV and the Seroprevalence of SARS-CoV-2

Stout, R. L.; Rigatti, S. J.

2021-05-03 hiv aids
10.1101/2021.04.29.21256302 medRxiv
Show abstract

ImportanceHealthy HIV-positive insurance applicants have a similar risk of infection and produce a similar antibody response as HIV-negative applicants infected with COVID-19. ObjectiveStudy the seroprevalence and immune response to COVID-19 in healthy HIV-positive life insurance applicants. DesignFrom January 2020 to March 2021, we examined the seroprevalence of COVID-19 in all HIV-positive applicants. Antibody level in 340 age and sex matched COVID-19 positive applicants, 170 HIV-positive and 170 HIV negative, are compared. The data was de-identified of all personal information and separated by month, age and sex. ParticipantsSelf-reported healthy HIV positive life insurance applicants were tested for antibodies to COVID-19.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.